Abstract:Cancer arises from the accumulation of genetic alterations, leading to the production of mutant proteins processed and presented as neoantigens on the surface of malignant cells. These can be derived from missense mutations or large insertions, deletions or translocations that produce indels and/or gene fusions. A major hurdle in developing cell-based therapies that engage the immune system against targets preferentially expressed on tumor cells is our inability to prioritize neoantigens due to insufficient knowledge of what drives immunogenicity. Accumulating evidence suggests CD8+ T cells recognize and mount effective responses against neoepitopes across various cancers, and both immune- and tumor-centric parameters play a role in this. However, it isn't known how the TCR repertoire drives antitumor responses, whether different patients with the same cancer type and similar HLAs generate comparable responses, or if differences in TCR specificity against conserved neoepitopes can be exploited to generate effective TCR-T cell-based therapies. To address these shortcomings and provide additional therapeutic options for patients with cancer, the goal of this research was to comprehensively assess the factors contributing to differences in tumor immunogenicity across different classes of antigens and define the principles of CD8+ T cell immune recognition that shape these responses. We hypothesized that different classes of antigens would have different peptide affinities and stabilities and in turn, affect the diversity of the naïve TCR repertoire. Furthermore, TCRs whose cognate antigen is highly dissimilar to self would have a higher probability of generation (Pgen). To test this, we performed peptide exchange assays using antigen presenting beads expressing HLA-A*02:01 to measure peptide-HLA (pHLA) affinity and stability. Naïve CD8+ T cells were then isolated from healthy donor PBMCs expressing HLA-A*02:01 and co-cultured with matched monoallelic K562 cells or autologous dendritic cells pulsed with viral and cancer antigens for a two-week period. On day 14, scRNA-seq and scTCR-seq were performed to characterize CD8+ transcriptional profiles, TCR diversity, and Pgen. Interestingly, our initial studies indicated that gene fusions, which display a greater distance from self than SNVs, have greater exchange rates, affinity, and stability compared to SNVs, but similar to viral antigens. While all antigens were able to induce CD8+ T cell expansion in co-culture assays, gene fusions and viral antigens generated the greatest frequency of antigen-specific CD8+ T cells and these TCRs tended to have a higher Pgen suggesting there may be an evolutionarily conserved mechanism in how specific TCR clonotypes are generated against evolutionarily encountered antigens and/or antigens with a high dissimilarity to self. Surprisingly, the number and diversity of the neoantigen-specific responses were heterogeneous and, in some cases, unique to the donor, which suggests there is a difference in donors' ability to generate private vs public TCRs. Citation Format: Jessica L. Schmeling, Anthony E. Zamora. Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B045.

Increased ‘selfness’ in the tumor emerges as a possible immune sculpting mechanism: A pan-cancer data analysis of 32 solid tumors in TCGA

Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer

Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer

Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples

Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling

Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy.

Abstract 1152: Pan-cancer single-cell and subcellular characterization of lymphoid aggregates and tertiary lymphoid structures using high-plex spatial molecular imaging

The Immunoscore: Colon Cancer and Beyond

Abstract B045: Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses

Conserved principles of spatial biology define tumor heterogeneity and response to immunotherapy

Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census

The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Abstract 1515: Tertiary lymphoid structures restrain cancer evolution by supporting stem-like CD8+ T cells for sustained anti-tumor immunity

The Immune Landscape of Cancer

Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

The role of TGF-β pathway alterations in immune regulation as a potential pan-cancer biomarker in immunotherapy